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IMMUNIZATION WITH SURFACE IMMUNOGENIC PROTEIN INDUCES A 
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The Group B streptococcus (GBS) is the leading cause of neonatal sepsis and meningitis in 
developed countries and an emerging pathogen in adults. A neonatal infection occurs predominantly 
during the delivery by either inhalation or ingestion of contaminated secretions of the mother’s 
vagina. Maternal screening by rectovaginal GBS colonization at 35–37 weeks of gestation, with 
subsequent intra-partum antibiotic prophylaxis (IAP) at the onset of labor, is implemented in some 
countries to prevent newborn invasive by GBS. Currently, there are not vaccines to prevent the 
devastating consequences of GBS and a glycoconjugate vaccine is under clinical experimentation 
(Clinical Trials Phase III). 
The Surface Immunological Protein (SIP) of GBS is highly immunogenic and conserved between 
different serotypes of this bacterium. The SIP had been described to induce antibodies type IgG that 
induces protective immunity in animal model challenged intraperitoneally with GBS. 
Here we describe the immunization with SIP mixed with an AbISCO-100 adjuvant in mice model 
challenged to GBS vaginal infection. The vaccine has demonstrated to decrease the GBS 
colonization in infected mouse. The SIP immunization has also increased the circulating IgA, IgG 
and IgG2a levels against SIP and antigen-specific circulating levels of IFN- ƴ and IL–2. In 
conclusion, we have demonstrated that a simple and effective vaccine is able to prevent GBS 
colonization. To our knowledge, is the first report the SIP-based vaccine reduces the vaginal GBS 


























SGB	  clinical	  isolates	   Expression	  and	  purifica5on	  rSP	  




SGB	  (1	  x	  10ˆ6	  UFC)	  







IgG,IgG1,IgG2a	   Evalua5on	  de	  IgA	  
Obtaining	  rSIP	  and	  immunological	  evalua5on	  
Group	  1:	  rSiP	  +	  AbISCO	  
Group	  2:	  rSiP	  +	  PBS	  1X	  
Group	  3:	  rSiP	  +Aluminum	  hydroxide	  
Group	  4:	  PBS	  1X	  
Group	  5:	  PBS	  1X	  +	  AbISCO	  
Group	  6:	  Unimmunized/challenged	  
1	  




SGB	  (1	  x	  10ˆ6	  UFC)	  
Bacterial	  count	  Weight	  determina5on	  
2	  
Adop5ve	  transfer	  of	  immunity	  
Group	  1:	  	  PBS	  1X	  
Group	  2:	  rSiP	  +	  AbISCO	  Serum	  
Group	  3:	  rSiP	  +	  AbISCO	  (CD4+/CD8+	  mix	  cells)	  
Group	  4:	  Naive	  cells	  
Group	  5:	  Unimmunized/challenged	  
	  
 METHODS ABSTRACT 
Figure 1. Weights of groups immunized and challenged with SGB. 
Groups were given an immunization and 2 boosters of 100 µL 
each of their respective doses. Weights were measured daily from 
the day of the challenge to the day the animals were sacrificed. 
Figure 2. IgA antibody titers of groups immunized and 
challenged with SGB. ELISA was developed using an anti-
mouse IgA antibody conjugated to the enzyme alkaline 
phosphatase and read in an ELISA reader at 405nm. 
Figure 3. IgG antibody titers of groups immunized and 
challenged with SGB. ELISA was developed using an anti-
mouse IgA antibody conjugated to the enzyme alkaline 
phosphatase and read in an ELISA reader at 405nm. 
 
Figure 4. Analysis of IgG1 and IgG2 antibodies of groups immunized and challenged with SGB. ELISA was developed using anti-
mouse IgG1 and IgG2 antibodies, respectively, conjugated to the enzyme alkaline phosphatase and read in an ELISA reader at 405nm. 
The positive control was an antigen of a kit for measuring the subclasses of (PD PharmingenTM). P < 0,05 (*). 
Figure 5. Evaluation of cytokines in groups of mice immunized and challenged with SGB. A: Levels of IFN-y liberated 
by mice immunized and challenged with SGB. B: Levels of IL-4 liberated by mice immunized and challenged with SGB. 
C: Levels of IL-2 liberated by mice immunized and challenged with SGB. The control without stimulus was a group 
without presence of the protein and without SGB challenge. P < 0,05 (*). 
 
Figure 6. Counts of bacterial colonies seeded in blood 
agar plates. The samples were vaginal washes of mice 
submitted to immunization and posterior infection with 
serotype III SGB. P < 0,05 (*). 
 
Figure 7. Graph weights of the groups subject to immunity transfer 
experiment and challenged with GBS. The groups were immunized with 
100 µL of each dose as corresponded. The immunization routes were: 
group 1X PBS and serum was intraperitoneally, while for groups mix-CD4 
+ CD8 + and CD4 +, CD8 + naive the immunization route was intravenous. 
Mice were infected with the bacteria 24 hours after immunization and their 
weights were measured from that day until 72 hours later. The number of 
mice used per group was n = 3. 
Figure 8. Bacterial count of the colonies on blood agar seeded. In 
spiked samples are plates vaginal washes mice subjected to transfer 
immunity and subsequent infection with GBS serotype III. The 
number of mice per group corresponded to a n = 3. 
The rSIP protein  was purified and formulated with AbISCO like vaccine prototype. We observed that both experimental groups immunized with rSIP-AbISCO and rSIP alone decreased 
the GBS vaginal colonization compared with others experimental groups (Figures 1-6). Furthermore, our data suggest that the immune response induced by our vaccine is balanced 
(cellular/humoral), but with a tendency towards a cellular immune response (Figures 7-8). 
RESULTS  
CONCLUSIONS  
• Our vaccine formulation is able to prevent GBS vaginal 
colonization in murine model, also we observed balanced Th1/Th2 
immune response but with a tendency to cell type response. 
• We analyzed passive immunity transfer. Healthy mice were 
infused with serum or a mixture of CD4/CD8 cells and then 
challenged with GBS. We observed a low level of GBS vaginal 
colonization in both experimental groups. 
• Our experimental model may be useful by testing new vaccine 
formulation. 
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